Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Consensus Rating of "Hold" from Brokerages

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) has earned a consensus rating of "Hold" from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $9.40.

A number of equities analysts have recently weighed in on RXRX shares. Needham & Company LLC dropped their target price on Recursion Pharmaceuticals from $16.00 to $11.00 and set a "buy" rating on the stock in a report on Wednesday, September 4th. Leerink Partners lowered their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a research note on Tuesday, September 3rd. KeyCorp lowered their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an "overweight" rating for the company in a research note on Thursday, July 11th. Finally, Jefferies Financial Group lowered their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a research note on Tuesday, September 3rd.

Insiders Place Their Bets

In other news, COO Tina Marriott sold 6,000 shares of the firm's stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $8.13, for a total value of $48,780.00. Following the sale, the chief operating officer now owns 535,457 shares in the company, valued at approximately $4,353,265.41. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, Director Blake Borgeson sold 11,447 shares of the firm's stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $6.67, for a total value of $76,351.49. Following the completion of the transaction, the director now directly owns 7,089,007 shares of the company's stock, valued at $47,283,676.69. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Tina Marriott sold 6,000 shares of the firm's stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $8.13, for a total value of $48,780.00. Following the completion of the transaction, the chief operating officer now directly owns 535,457 shares of the company's stock, valued at approximately $4,353,265.41. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 201,682 shares of company stock valued at $1,332,933 over the last 90 days. 15.75% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC bought a new position in shares of Recursion Pharmaceuticals in the third quarter valued at about $25,000. Benjamin F. Edwards & Company Inc. bought a new position in shares of Recursion Pharmaceuticals in the first quarter valued at about $26,000. GAMMA Investing LLC raised its holdings in shares of Recursion Pharmaceuticals by 1,588.4% in the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company's stock valued at $48,000 after buying an additional 6,036 shares during the last quarter. Amalgamated Bank raised its holdings in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company's stock valued at $54,000 after buying an additional 2,459 shares during the last quarter. Finally, San Luis Wealth Advisors LLC bought a new position in shares of Recursion Pharmaceuticals in the third quarter valued at about $69,000. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Stock Down 4.2 %

Shares of RXRX traded down $0.28 during trading hours on Wednesday, reaching $6.33. The company's stock had a trading volume of 3,964,821 shares, compared to its average volume of 5,741,024. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -3.94 and a beta of 0.80. Recursion Pharmaceuticals has a 1-year low of $4.97 and a 1-year high of $15.74. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. The company has a 50 day moving average of $6.73 and a two-hundred day moving average of $7.75.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05). The business had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. Recursion Pharmaceuticals's revenue for the quarter was up 30.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.38) EPS. As a group, research analysts predict that Recursion Pharmaceuticals will post -1.58 EPS for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.